{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"35"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"40"}],"units":"Participants"}],"description":"The feasibility of this approach will be assessed in terms of obtaining an actionable response from the proposed assay in at least 50% of patients examined.","groups":[{"description":"Patients undergo collection of bone marrow aspirate and blood for high-throughput drug sensitivity assay and mutational analysis using next generation sequencing. Patients and their treating physicians receive the results of the tests. Treatment decisions are then made by the patients and their treating physicians.\n\nBiospecimen Collection: Undergo collection of bone marrow aspirate and blood\n\nHigh Throughput Screening: Anti-tumor drugs are tested against myeloma cells in the laboratory, in a high-throughput drug sensitivity assay\n\nLaboratory Biomarker Analysis: Correlative studies","id":"OG000","title":"Device Feasibility (High-throughput Assay, Sequencing)"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Of the 40 patients enrolled, 35 obtained actionable response from the assay within 21 days.","reportingStatus":"POSTED","timeFrame":"Up to 21 days","title":"Number of Participants With Actionable Assay Response","type":"PRIMARY","unitOfMeasure":"Participants"}